Transtek(SZ:300562) Sou Hu Cai Jing·2026-02-10 13:22Core Viewpoint - The financial performance of Loxin Medical (300562) shows a slight increase in revenue and a significant rise in net profit for the first three quarters of 2025, indicating potential growth in the home medical equipment and remote health management sectors [2]. Financial Performance Summary - For the first three quarters of 2025, Loxin Medical reported a main revenue of 757 million yuan, a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.68 million yuan, reflecting a year-on-year increase of 29.99% [2]. - The net profit after deducting non-recurring items was 59.62 million yuan, up by 19.35% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 236 million yuan, a decrease of 8.53% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 23.39 million yuan, showing a significant increase of 49.2% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 21.55 million yuan, up by 22.64% year-on-year [2]. - The company's debt ratio stands at 30.1%, with investment income of 4.33 million yuan and financial expenses of 2.01 million yuan [2]. - The gross profit margin is reported at 35.59% [2]. Market Activity Summary - As of February 10, 2026, Loxin Medical's stock closed at 14.88 yuan, with an increase of 0.47% [1]. - The turnover rate was 3.46%, with a trading volume of 56,000 hands and a transaction amount of 83.32 million yuan [1]. - On February 10, the net outflow of main funds was 9.36 million yuan, accounting for 11.23% of the total transaction amount [1]. - The net inflow of retail funds was 2.34 million yuan, representing 2.81% of the total transaction amount [1]. - The net inflow of speculative funds was 7.01 million yuan, making up 8.42% of the total transaction amount [1].